CRISPR Therapeutics AG (CRSP) Preferred Stock Liabilities (2015 - 2016)

CRISPR Therapeutics AG has disclosed Preferred Stock Liabilities across 2 years of filings, most recently posting $128.6 million for Q3 2016.

• In Q3 2016, Preferred Stock Liabilities changed N/A year-over-year to $128.6 million; the TTM figure through Sep 2016 stood at $128.6 million (changed N/A YoY), while the FY2015 annual figure was $30.4 million, up 496.75% from the prior year.
• Preferred Stock Liabilities came in at $128.6 million for Q3 2016 at CRISPR Therapeutics AG, up from $30.4 million in the prior quarter.
• In the past five years, Preferred Stock Liabilities ranged from a high of $128.6 million in Q3 2016 to a low of $30.4 million in Q4 2015.